Ingene

InGene is a South Korean precision medicine company specializing in molecular diagnostics and liquid biopsy technologies. Founded in 2015, the company has developed the proprietary i-G-N-S platform, which leverages next-generation sequencing (NGS) to provide high-sensitivity detection of circulating tumor DNA (ctDNA) and other biomarkers. Their product portfolio includes the InGene-L series for liquid biopsy-based cancer monitoring and the InGene-H series for hereditary cancer screening. InGene's services are designed to support targeted therapy selection and companion diagnostics, helping clinicians tailor treatment plans to the genetic profile of individual patients. The company is publicly traded on the KONEX exchange and continues to expand its footprint in the global precision oncology market.